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Allelic loss at the chromosomal region 10q23–25 has been reported
for prostate and several other cancers (Gray et al, 1995; Bose et al,
1998; Cairns et al, 1998; Feilotter et al, 1998; Maier et al, 1998;
Robertson et al, 1998). Analysis of loss of heterozygosity (LOH) in
microdissected prostate tumours initially placed the minimum
region of loss between the markers D10S1644 (AFMa124wd9) and
D10S583 (Gray et al, 1998) and was subsequently refined to a
region of 400 kb between D10S1765 and D10S541 (Gray, unpub-
lished data). A putative tumour suppressor gene called PTEN,
MMAC1 or TEP1 (Li and Sun, 1997; Li et al, 1997; Steck et al,
1997) has been located within this region and was mutated in
glioblastomas, endometrial and prostate tumours (Cairns et al,
1997; Rasheed et al, 1997; Tashiro et al, 1997; Feilotter et al, 1998;
Gray et al, 1998). In addition, germline PTEN mutations have been
found to be associated with Cowden’s disease (Liaw et al, 1997)
and related syndromes such as Bannayan-Zonana syndrome
(Marsh et al, 1997).
PTEN has regions of homology to chicken tensin and auxilin
(Li et al, 1997) and incorporates phosphatase domains which are
active against both lipid and protein substrates (Myers et al,
1997; Maehama and Dixon, 1998). Evidence for a tumour
suppressor function for PTEN comes from experiments in which
transfection of PTEN into a medulloblastoma cell line null 
for PTEN expression caused inhibition of proliferation and
anchorage-dependent growth (Cheney et al, 1998). Total gene
disruption resulted in embryonic lethality in mice, whereas
animals heterozygous for PTEN expression showed hyperplastic-
dysplastic changes in epithelial tissues and an increased
incidence of tumours (Di Cristofano et al, 1998). The tumour
suppressor activity of PTEN may result from its demonstrated
ability to dephosphorylate the second messenger phosphatidy-
linositol-3,4,5-triphosphate (PIP3), thereby restricting cell
growth and allowing apoptosis to occur (Maehama and Dixon,
1998; Tamura et al, 1998). In addition, the ability of PTEN to
dephosphorylate focal adhesion kinase may prevent cell migra-
tion (Tamura et al, 1999), and the inactivation of PTEN has
recently been associated with increased angiogenesis in prostate
carcinomas (Giri and Ittmann, 1999).
Analysis of the PTEN mRNA species has revealed a complex
pattern of different sized transcripts (Steck et al, 1997; Gray et
al, 1998) some of which could have arisen from alternate splice
events. Additionally a pseudogene for PTEN (y PTEN) has been
identified on chromosome 9 which has been claimed to be tran-
scribed (Dahia et al, 1998). In this paper we investigate origins
of the major mRNA species seen on Northern blots and describe
BAC/PAC coverage of the region along with the exact location
of several polymorphic markers and identification of single
nucleotide polymorphisms.
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Summary PTEN, a putative tumour suppressor gene associated with prostate and other cancers, is known to be located within the
chromosomal region 10q23.3. Transcription of the PTEN gives rise to multiple mRNA species. Analyses by Northern blots, using cell lines
which express PTEN together with cell lines which have lost the PTEN or carry a truncated version of the gene, has allowed us to
demonstrate that the pseudogene is not transcribed. In addition, 3¢ RACE studies confirmed that the multiple mRNA species arising from the
gene probably result from the use of alternative polyadenylation sites. No evidence for tissue- or cell-specific patterns of transcription was
found. Analysis by 5¢ RACE placed the putative site for the start of transcription around 830 bp upstream of the start codon. A map of the
location of the PTEN gene with a series of overlapping YAC, BAC and PACs has been constructed and the relative position of eight
microsatellite markers sited. Two known and one novel marker have been positioned within the gene, the others are in flanking regions. The
more accurate location of these markers should help in future studies of the extent of gene loss. Several polymorphisms were also identified,
all were within introns. Four of the common polymorphisms appear to be linked. In blood, DNA from 200 individuals, including normal, BPH
and prostate cancer patients, confirmed this link. Only two samples of 200 did not carry the linked haplotype, both were patients with
advanced prostate cancer. It is possible that such rearrangements within PTEN could be evidence of predisposition to prostate cancer in this
small number of cases. © 2000 Cancer Research Campaign
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YAC, BAC and PAC isolation
YAC 821D2 was identified from the CEPH Mega YAC library by
using the ‘infoclone’ program (Chumakov et al, 1995) to screen
for YACs bearing CA repeat markers spanning the minimal region
and a clone obtained from the UK HGMP Resource Centre in
Cambridge. BAC and PAC clones were identified from Human
BAC pools and RPCI Human PAC libraries (Research Genetics)
by polymerare chain reaction (PCR) screening with CA repeat
markers. BAC146B18 was isolated as a clone from which we
could amplify the T7 (telomeric) end of BAC46B12 and whose
centromeric end sequence could be amplified from BAC122L22.
Insert size was estimated by restriction enzyme digests using
infrequently cutting restriction endonucleases, followed by
separation by pulsed field gel electrophoresis using manufac-
turer’s recomended conditions (BioRad).
Cell lines
The lymphoblastoid line Bristol 8 (BRI8) has been previously
described (Gray et al, 1998), DU145, PC3 and A172 were from
ATCC, and UMUC3 was provided by Prof. M Knowles (Aveyard
et al, 1998). A second vial of DU145 was obtained from Dr R
Schrock (Introgen Therapeutics Inc.). All lines were grown in
Dulbecco’s modified Eagles medium (DMEM) supplemented with
10% fetal calf serum.
Exon, intron and microsatellite marker amplification
Exons were amplified as previously described (Gray et al, 1998)
using primers based on intronic sequences. Primer sequences for
Chemical Cleavage of Mismatches (CCM) were obtained from
BAC sequence data obtained within the laboratory, and the 5¢ end
of each 3¢ primer was PIG-tailed to facilitate CCM (Brownstein 
et al, 1996). CCM cycling conditions were as follows: 10 min at
96°C followed by 35 cycles of 96°C for 30 s, 49–60°C for 30 s,
72°C for 5 min in a Perkin-Elmer 9600 thermal cycler and using
Taq Gold (Perkin-Elmer). Annealing temperature was dependent
on primer pair used.
BAC sequencing
BACs were prepared using a modified Qiagen midi prep method.
Two hundred millilitres cultures were grown in selective medium
and processed by the Qiagen midi prep protocol, except that 15 ml
of P1, P2 and P3 were used in place of the recommended 4 ml.
After centrifugation DNA was precipitated from the supernatant
with isopropanol, the pellet washed with 70% ethanol and
resuspended in 1 ml of dH2O (heavy water) and 0.25 ml of 10 M
NH4Ac. Non-soluble particles were removed by centrifugation and
DNA was ethanol precipitated. After centrifugation, the pellet was
redissolved in 2 ml of H2O and 10 ml of QBT buffer. Qiagen
protocols were followed thereafter. The DNA was finally resus-
pended in a total of 120 ml, and 6–8 ml used per sequence reaction.
DNA sequence reactions were performed using Big Dye
Terminator Cycle Sequencing Ready Reaction Kits (Perkin-
Elmer) and analysed on an ABI377.
Chemical cleavage of mismatches
CCM in heteroduplexes formed between two different alleles was
performed using the hydroxylamine method (Rowley et al, 1995).
The reaction products were analysed on a 6% acrylamide/urea gel
with 12-cm plates at 950 volts for 3.5–4 h on an ABI 377 DNA
sequencer. The results were analysed using Genescan 2.1.1 soft-
ware. When cleavage products were detected, PCR products span-
ning the relevant interval were purified using Qiagen PCR cleanup
columns and sequenced using the amplification primers to deter-
mine the exact nature of the mismatch.
5¢- and 3¢-rapid amplification of cDNA ends (RACE)
5¢- and 3¢-RACE reactions were performed using 0.1–0.2 ng of
Marathon-Ready prostate cDNA (Clontech) and Advantage-GC
cDNA PCR buffer and polymerase mix (Clontech). PCR reactions
were carried out in a 9700 thermal cycler (Perkin-Elmer) in a total
volume of 50 ml. Cycling parameters for 5¢-RACE were either
94°C for 1 min followed by 35 cycles of denaturation for 30 s and
extension for 3 min at 68°C or ‘touchdown’ PCR where a 30 s
denaturation step was followed by 5 cycles of 94°C for 10 s and
72°C for 4 min, 5 cycles of 94°C for 10 s and 70°C for 4 min and
25 cycles of 94°C for 10 s and 67°C for 4 min. When touchdown
PCR conditions were used for the primary PCR, the nested PCR
parameters were denaturation for 30 s followed by 5 cycles of
94°C for 10 s, 62°C for 30 s, 68°C for 2 min, 5 cycles of 94°C for
10 s, 60°C for 30 s, 68°C for 2 min and 25 cycles of 94°C for 10 s,
59°C for 30 s, 68°C for 2 min. The following primers were used 
in the primary 5¢-RACE reactions: GSP1, 5¢-GGCAGAA-
GCTGCTGGTGGCGGGG; GSP2, 5¢-GCCGCCGTGTTGGAG-
GCAGTAGAAGGGG; GSP3, 5¢-AACTGAGCGCAGTCGCGT-
CCCAGCGC and AP1 (Clontech). In the nested 5¢-RACE
reactions the primers were NGSP1, 5¢-GGAAATGGCTCTG-
GACTTGGCGG; NGSP2,5¢-ACCAACTCTCCGGCGTTCCC-
AGC; NGSP3, 5¢-CAGCGCATAAAGAGTCCTGCCAC and AP2
(Clontech). Cycling parameters for 3¢-RACE were 94°C for 1 min
followed by 6 cycles of 94°C for 10 s and 67°C for 3 min and 30
cycles of 94°C for 10 s and 64°C for 4 min. The following primers
were used in the 3¢-RACE reactions in combination with the 
AP1 and AP2 primers from Clontech: 3¢GSP2, 5¢-CATC-
CACAGGGTTTTGACAC; 3¢NGSP2, 5¢-GGTTGTGTAGCTGT-
GTCATG; 3¢GSP3, 5¢-CGGGTTAGGGCAATGGAGGGGAA-
TGC; 3¢NGSP3, 5¢-CGAGGAATTGGCCGCTGTCACTGC. The
RACE products were gel purified (Qiagen) and cloned into
pGEM-T Easy Vector (Promega) or sequenced directly.
RNA and Northern analysis
Messenger RNA was extracted from the cell lines UMUC3, BRI8,
DU145 and A172 using FastTrack RNA isolation kit (Invitrogen).
Five micrograms of mRNA from each cell line were size-fraction-
ated on a 1% formaldehyde agarose gel and transferred to a
Hybond N+ membrane (Amersham) using 20 ´ SSC
(sodium–saline citrate) as transfer buffer. A full length PTEN
cDNA probe was labelled with 32P-dCTP using Megaprime DNA
labelling system (Amersham). A probe fragment was generated
for the 3¢UTR region by PCR using primers 5¢-GACTGAAAG-
GTTTTCGAGTCC and 5¢-GAGGAGCTACAAAGGACTTGG
and labelled with 32P-dCTP as described previously (Gray et al,
1998). RNA hybridization was carried out using ExpressHyb
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instructions. Membranes were washed in 2 ´ SSC and 0.1%
sodium dodecyl sulphate (SDS) at room temperature for 50 min
with several changes of wash solution. X-ray film (Fuji) was
exposed to the Northern blots in the presence of 2 screens for 1–3
days.
RESULTS
LOH of the chromosomal region around PTEN occurs in several
cancer types, and to allow a more detailed analysis of this loss a
map of overlapping BACs and PACs was constructed and several
microsatellite markers positioned on this map along with the
exons/introns of PTEN (Table 1). The PTEN gene covers approxi-
mately 100 kb and the markers D10S2491 and D10S1765 which
are located 5¢ or telomeric to the gene were found to be identical.
D10S608 which has previously been used to map PTEN LOH is
not located within the designated region and is at least 160 kb
telomeric of the PTEN gene. Markers AFMa086wg9 (intron 2) and
D10S2492 (intron 8) are located within PTEN. In addition a
further CA repeat was identified from sequencing within intron 8
which was heterozygous in 45% of a sample of blood DNAs 
from a group of 200 individuals when these were analysed by
microsatellite methods.
Comparison of genomic and BAC sequencing with database
sequences for intron 1 (Genebank sequence – BAC 265N13)
showed that there was probably a deletion in the database submis-
sion. Genomic sequences we have obtained from around PTEN
have been lodged with Genbank (Accession Nos AF143312,
AF143313, AF143314, AF143315, AF143316, AF143317 and
AF143318).
In addition to microsatellite markers a search for single
nucleotide polymorphisms was undertaken. PTEN intronic
sequence primers were used to PCR amplify 1–1.5 kb fragments of
DNA from 20 normal human blood samples. PTEN regions ampli-
fied included 1.9 kb downstream of exon 3, approximately 6.7 kb
upstream of exon 4, all of intron 4, 1.5 kb downstream of exon 5,
and 1 kb downstream of exon 6. These fragments, which covered
around 12 kb of sequence in total, were analysed by CCM to
identify polymorphisms and potential changes were confirmed by
sequencing. Polymorphisms and levels of heterozygosity are listed
in Table 2; some of these polymorphisms have been described
previously but confirmed by CCM and sequencing during the
course of our studies.
Four polymorphic markers located within the PTEN gene had a
similar frequency of heterozygosity of around 40% and were used
to analyse the DNA obtained from the blood of 200 individuals
(these included 97 prostate cancer patients, 43 patients with benign
prostatic hyperplasia and 60 other non-cancer patients). From this
analysis it appeared that two distinct haplotypes existed. For the
four markers 1, 4, 5 and 8 respectively (Table 2), the linkage was
either G,A,+,G or A,G,–,T. Of the 200 DNAs tested, 45.5% were
heterozygous at each of the markers, 12% were homozygous for
A,G,–,T haplotype and 41.5% were homozygous for G,A,+,G
haplotype. Only two out of 200 individuals did not carry the linked
haplotype in their blood DNA and both were cancer patients, their
genotypes were A,G,–,G/T and A,G/A,+/–,G/T.
To analyse the complex pattern of transcription found for PTEN
a number of cell lines were studied. Five cell lines were analysed
by PCR for the presence or absence of PTEN and yPTEN. To
distinguish PTEN from yPTEN, primers complementary to intron
sequences were used to amplify PTEN exons (yPTEN is processed
and has no introns). In cell lines where all nine PTEN exons were
present these exons were sequenced. The B lymphoblastoid cell
line BRI8 and the prostate line DU145 contained all PTEN exons
and carried no mutations. DU145 has been described as carrying a
mutation at codon 145 (Li et al, 1997); we were unable to find this
mutation in two independent sources of DU145. Consistent with
published results the glioblastoma cell line A172 contains only
exons 1 and 2, and the bladder cell line UMUC3 has lost all PTEN
exons (Li et al, 1997; Steck et al, 1997; Aveyard et al, 1998). PC3
cells used for these studies contained only exons 1 and 2. The pres-
ence of the PTEN pseudogene in these cell lines was determined
using PCR primers from the boundary of exons 3 and 4 and from
exon 6, which could only generate a product when no intronic
sequences were present. PTEN pseudogene sequences were found
to be present in all cell lines examined. Multiple PTEN transcripts
(Steck et al, 1997; Gray et al, 1998) were evident in BRI8 and
DU145 cells, but no mRNA transcripts were detected in UMUC3
cells which were null for PTEN but positive for the yPTEN. A
shortened transcript was detected in the mRNA from the A172 cell
line which has only exons 1 and 2 (Figure 1).
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Table 1 Microsatellite and PTEN content of YACs, BACs and PACs and their alignment in the region of LOH
Approx D10S D10S D10S Exon Exon AFM Exons D10S 8/9 Exon D10S
size 608 215 1765 1 2 a086wg9 3–8 2492 CA 9 541
(kb) (2491)
Y738B12 1330
Y821-D2 1141
P72G8 165
P274D21 150
B2F20 90
B46B12 230
B60C5 160
B146B18 110
B122L22 105
Black squares indicate the presence and white squares the absence of the marker or exon. Primers used for the amplification of the exons can be
found in the Genome Database (http://www.GDB.org) with the exception of CA8/9 which was amplified using the primer pair 5¢-CAGCACTTTGG-
GAGGCTAAG/5¢- TTTCACTTAAAACGTGCAGGGG. B146B18 overlaps B122L22 and B60C5 but does not contain a marker or exon.Previously we reported that a 121 bp probe from position 338 to
459 upstream of the ATG start codon of PTEN hybridized to a
single transcript on Northern blots (Gray et al, 1998), which could
be evidence of alternate splicing. However, when this probe was
used on a Northern blot containing mRNA from BRI8, DU145,
UMUC3 and A172 cells a band of approximately 5.5 kb was
detected in cell lines that are both positive and negative for PTEN.
Exact alignment of Northern blots showed that this band was
marginally smaller than the expected 5.5 kb transcript detected
with a PTEN exon 1 probe (data not shown; Gray et al, 1998).
3¢-RACE was employed to confirm the use of alternate
polyadenylation sites, which would give rise to multiple transcripts,
and extension of transcription beyond the end of the published
MMAC1 sequence (GenBank accession U92436). 3¢-RACE prod-
ucts generated using primers 3¢NGSP2 (located 204 bp downstream
of the PTEN stop codon) and AP2 terminated with poly-adenosine
(poly-A) tails either 290–300 bp downstream from the stop codon
and within 20–40 bp of two AAUAAA elements, or where the
published  MMAC1 sequence terminates 910 bp from the stop codon
(data not shown). 3¢-RACE products produced using the primers
3¢NGSP3 and AP2 terminated in the vicinity of the end of the
MMAC1 sequence with a poly-A tail. Longer 3¢-RACE products
were not generated with the conditions used. However, while this
work was in progress a search of the GenBank database revealed
one EST, IMAGE clone 361374 (Accession Nos AA017563 and
AA017584), which extended 271 bp downstream of the end of the
MMAC1 sequence, indicating that transcription can progress beyond
the end of the MMAC1 sequence. Furthermore, a probe from the 3¢
untranslated region located 2471–2680 bp downstream of the termi-
nation codon, and prior to a group of polyadenylation signals in the
genomic sequence, gave a single band on Northern blots equivalent
to the largest mRNA species (Figure 2), providing further evidence
for transcription extension.
To identify the putative transcription start site and to explore the
possibility that long PTEN transcripts may result from alternate
splicing involving novel 5¢ exons, 5¢ RACE was performed using
three sets of nested primers: GSP1 + NGSP1, GSP2 + NGSP2,
GSP3 + NGSP3. The PCR primer set GSP3 + NGSP3, located 
860 nt upstream of the longest published cDNA sequence (Li and
Sun, 1997), did not result in a PCR product suggesting the coding
sequence does not extend into this region. Several PCR fragments
were generated using GSP1 + NGSP1 and GSP2 + NGSP2 which
displayed sequence identity with previously published sequence
(Li and Sun, 1997). The largest fragment extended 827 bp in the 5¢
direction from the start codon, 35 bp further than the TEP1 cDNA
sequence. A second fragment also finished at this point while a
third finished 824 bp from the start codon.
DISCUSSION
The PTEN gene covers over 100 kb of a 400 kb region of allelic
loss common to most prostate tumours (Gray et al, 1995).
Although the detection frequency of PTEN mutations in prostate
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Figure 1 Northern blot analysis of mRNA from cell lines probed with a
PTEN cDNA clone. BRI 8 – B lymphoblastoid cell line; DU145 – prostate cell
line; UMUC3 – bladder cell line; A172 – glioblastoma cell line
Figure 2 Northern blot analysis of multiple tissue blots probed with: (A) a
PTEN cDNA; and (B) a probe from sequence located 3 kb downstream of the
PTEN termination codon 
Table 2 Polymorphisms in PTEN and their frequency in normal DNA samples.
No. Intron Position Polymorphism Heterozygosity (%)
1 1 – 96 exon 2 A/G 40
2 3 + 329 exon 3 T/C 15
3 3 + 3362 exon 3 A/C 6
4 3 – 1606 exon 4 A/G 39
5 4 + 109 exon 4 ATCTTins/del(+/–) 36
6 4 + 403 exon 4 T/C 5
7 7 + 461 exon 6 G/A 6
8 8 + 32 exon 8 T/G 37tumours is lower than anticipated (Cairns et al, 1997; Teng et al,
1997; Feilotter et al, 1998; Gray et al, 1998), the frequency of
mutations in other tumour types such as glioblastoma and endome-
trial carcinoma (Liaw et al, 1997; Rasheed et al, 1997; Tashiro et
al, 1997; Teng et al, 1997; Duerr et al, 1998; Risinger et al, 1998),
taken together with the data from in vitro cell growth experiments
and the targeted disruption of PTEN in mice (Di Cristofano et al,
1998), support the view that PTEN is a tumour suppressor gene.
We have mapped CA repeat markers D10S608, AFMa086wg9,
D10S2491 and D10S2492 precisely around PTEN and identified a
number of other common intragenic polymorphisms including a
novel CA repeat within intron 8 of PTEN. These polymorphisms
could prove useful for future studies on PTEN and will provide a
panel of markers for more detailed mapping of LOH. We have also
identified the existence, within the population, of two distinct
haplotypes covering this region, although no polymorphisms were
found within the coding sequence of PTEN.
We have attempted to dissect the complex PTEN mRNA tran-
script profile. Two cell lines, UMUC3 and A172, were used to
determine whether a known pseudogene on 9p21 (Dahia et al,
1998) contributes to the pattern of PTEN mRNA transcripts. Both
cell lines retain the pseudogene but UMUC3 has completely lost
both copies of the PTEN gene and A172 retains exons 1 and 2 of
PTEN. On Northern blot analysis no transcript was identified for
UMUC3 and an altered message profile was found in A172 cells
consistent with the truncated copy of PTEN present in this cell
line. These results indicate that the pseudogene is not transcribed
and does not contribute to any of the transcripts identified in cell
lines studied. The pseudogene was originally identified by cloning
from RT-PCR implying that transcription was taking place (Kim 
et al, 1998) and has subsequently been reported as occurring as a
major mRNA species (Fujii et al, 1999). Although we cannot
exclude the possibility that there could be some cell/tissue-specific
transcription of the pseudogene, the similarity of the multiple
species seen on Northern blots with mRNA from a variety of
different tissues (Gray et al, 1998) and the PTEN-positive cell lines
described here, taken together with data described by others
(Dahia et al, 1998) makes it appear more likely that the pseudo-
gene is not transcribed.
We previously reported that a probe derived from the 5¢
sequence of PTEN detects only a 5.5 kb transcript whereas full
length cDNA probes or probes derived from individual exons all
give a complex pattern with major RNA species at 2.1 kb, 2.4 kb
and 5.5 kb (Gray et al, 1998). When this probe was used to analyse
RNA from PTEN null cells a single band was seen in both
UMUC3 and A172 which was identical to the pattern seen for
PTEN-expressing cells. Therefore this 5.5 kb band is distinct from
the similarly sized transcript detected with probes derived from the
PTEN coding region. Consequently it is unlikely to have arisen
from alternate PTEN splicing and is more likely to be the result of
cross-hybridization to an unrelated RNA with some sequence
similarity to the PTEN 5¢ UTR.
Published cDNA sequence of the PTEN 5¢ UTR extends 790 bp
upstream of the ATG translation start site. To determine the region
of initiation of transcription a commercial prostate cDNA library
was analysed by 5¢-RACE. The clones obtained extend the longest
previously reported cDNA sequence (Li and Sun, 1997) by 38
bases. Primers derived from genomic sequence 5¢ to this region
and 5¢ to the published TEP1 cDNA sequence did not produce a
PCR product. This suggests that the transcription start site is in the
region of the sequence described by Li and Sun (1997), which
would give a 5¢ untranslated sequence of around 827 bp, with a
gene sequence of 1209 bp and the first polyadenylation sites at 
60 bp and 290 bp from the translation termination signal. These
distances correlate with the size of the smaller mRNA species of
2.1 and 2.4 kb seen on Northern analysis (Gray et al, 1998). The
larger 5.5 kb species is likely to result from a further poly-
adenylation site approximately 3 kb downstream of the second
polyadenylation signal. This conclusion is supported by Northern
blot analysis where the 5.5 kb mRNA species was identified with a
probe from a region 3 kb downstream of the termination codon
(Gray et al, 1998). cDNA sequences in the database and 3¢ RACE
experiments confirm that alternative polyadenylation sites are used
and that poly-A tails are added at the equivalent position to the 2.1
and 2.4 kb and that longer species are also transcribed. This
analysis taken in conjunction with the analysis of PTEN null and
PTEN truncated cell lines suggests that the complex pattern of
mRNAs seen on Northern blots arises largely from alternative
polyadenylation sites and that no major contribution to this pattern
is made by pseudogene transcription, alternate splicing or cross-
hybridization to related gene family members. The significance of
the variable 3¢ UT sequences is unclear but regulatory elements in
this region in other genes have been associated with cell differenti-
ation (Rastinejad and Blau, 1993), mRNA stability particularly in
cancer cells (Rajagopalan and Malter, 1997) and tissue-specific
expression (Coy et al, 1999).
PTEN appears to be an important tumour suppressor gene which
is lost in many cancers. In some cases, particularly in glioblast-
omas and endometrial cancers, the presence of LOH and mutations
in the second gene is consistent with the Knudson two-hit hypoth-
esis (Knudson, 1991). In the case of prostate cancer, LOH is
common (Gray et al, 1995) but mutations in the remaining gene
are rare (Gray et al, 1998), although loss of transcription due to
methylation has been reported in some tumour samples (Whang 
et al, 1998). The detailed genomic map and an analysis of PTEN
transcripts should assist in the understanding of the genomic
changes which contribute to tumour progression by the inactiva-
tion of PTEN in prostate and other tumours.
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